Immune status following alemtuzumab treatment in human CD52 transgenic mice

Journal of Neuroimmunology

Volumn 261, Issue 1-2, 2013, Pages 29-36

  Turner, Michael J ^a   LaMorte, Michael J ^a   Chretien, Nathalie ^a   Havari, Evis ^a   Roberts, Bruce L ^a   Kaplan, Johanne M ^a   Siders, William M ^a  

^a SANOFI   (France)

Author keywords

Alemtuzumab; CD52; Immune status; Multiple sclerosis

Indexed keywords

ADENOVIRUS VECTOR; ALEMTUZUMAB; CD52 ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNE STATUS; IMMUNOCOMPETENCE; INNATE IMMUNITY; LYMPHOCYTE DEPLETION; MEMORY CELL; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRANSGENIC MOUSE;

ALEMTUZUMAB; CD52; IMMUNE STATUS; MULTIPLE SCLEROSIS;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CELLS, CULTURED; GLYCOPROTEINS; HUMANS; IMMUNITY, INNATE; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84880849711     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.04.018     Document Type: Article

References (20)

1. Clark R.A., Watanabe R., Teague J.E., Schlapbach C., Tawa M.C., Adams N., Dorosario A.A., Chaney K.S., Cutler C.S., Leboeuf N.R., Carter J.B., Fisher D.C., Kupper T.S. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci. Transl. Med. 2012, 4:117ra7.
2. Cohen J.A., Coles A.J., Arnold D.L., Confavreux C., Fox E.J., Hartung H.P., Havrdova E., Selmaj K.W., Weiner H.L., Fisher E., Brinar V.V., Giovannoni G., Stojanovic M., Ertik B.I., Lake S.L., Margolin D.H., Panzara M.A., Compston D.A. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012, 380:1819-1828.
3. Coles A.J., Compston D.A., Selmaj K.W., Lake S.L., Moran S., Margolin D.H., Norris K., Tandon P.K. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 2008, 359:1786-1801.
4. Coles A.J., et al. Leukocyte dynamics following alemtuzumab 2010.
5. Coles A.J., Fox E., Vladic A., Gazda S.K., Brinar V., Selmaj K.W., Skoromets A., Stolyarov I., Bass A., Sullivan H., Margolin D.H., Lake S.L., Moran S., Palmer J., Smith M.S., Compston D.A. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012, 78:1069-1078.
6. Coles A.J., Twyman C.L., Arnold D.L., Cohen J.A., Confavreux C., Fox E.J., Hartung H.P., Havrdova E., Selmaj K.W., Weiner H.L., Miller T., Fisher E., Sandbrink R., Lake S.L., Margolin D.H., Oyuela P., Panzara M.A., Compston D.A. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012, 380:1829-1839.
7. Cossburn M., Pace A.A., Jones J., Ali R., Ingram G., Baker K., Hirst C., Zajicek J., Scolding N., Boggild M., Pickersgill T., Ben-Shlomo Y., Coles A., Robertson N.P. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011, 77:573-579.
8. Costelloe L., Jones J., Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert. Rev. Neurother. 2012, 12:335-341.
9. Cox A.L., Thompson S.A., Jones J.L., Robertson V.H., Hale G., Waldmann H., Compston D.A., Coles A.J. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 2005, 35:3332-3342.
10. Gilleece M.H., Dexter T.M. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993, 82:807-812.
11. Hale G. Cd52 (Campath1). J. Biol. Regul. Homeost. Agents 2001, 15:386-391.
12. Hale G., Xia M.Q., Tighe H.P., Dyer M.J., Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990, 35:118-127.
13. Hu Y., Turner M.J., Shields J., Gale M.S., Hutto E., Roberts B.L., Siders W.M., Kaplan J.M. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009, 128:260-270.
14. Jones J.L., Phuah C.L., Cox A.L., Thompson S.A., Ban M., Shawcross J., Walton A., Sawcer S.J., Compston A., Coles A.J. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 2009, 119:2052-2061.
15. Jones J.L., Anderson J.M., Phuah C.L., Fox E.J., Selmaj K., Margolin D., Lake S.L., Palmer J., Thompson S.J., Wilkins A., Webber D.J., Compston D.A., Coles A.J. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010, 133:2232-2247.
16. Masuyama J., Yoshio T., Suzuki K., Kitagawa S., Iwamoto M., Kamimura T., Hirata D., Takeda A., Kano S., Minota S. Characterization of the 4C8 antigen involved in transendothelial migration of CD26(hi) T cells after tight adhesion to human umbilical vein endothelial cell monolayers. J. Exp. Med. 1999, 189:979-990.
17. Rao S.P., Sancho J., Campos-Rivera J., Boutin P.M., Severy P.B., Weeden T., Shankara S., Roberts B.L., Kaplan J.M. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 2012, 7:e39416.
18. Rowan W.C., Hale G., Tite J.P., Brett S.J. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int. Immunol. 1995, 7:69-77.
19. Thompson S.A., Jones J.L., Cox A.L., Compston D.A., Coles A.J. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J. Clin. Immunol. 2010, 30:99-105.
20. + regulatory T cells. Clin. Immunol. 2006, 120:247-259.